United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $532.24, for a total value of $5,056,280.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at $172,681,542.32. The trade was a 2.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Stock Down 0.8%

Shares of NASDAQ UTHR opened at $523.63 on Wednesday. The firm has a 50-day simple moving average of $546.23 and a 200-day simple moving average of $532.01. The stock has a market capitalization of $22.23 billion, a price-to-earnings ratio of 19.33, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the prior year, the business posted $6.63 earnings per share. The business’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, equities research analysts expect that United Therapeutics Corporation will post 26.65 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of analyst reports. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Raymond James Financial began coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $648.33.

Institutional Trading of United Therapeutics

Several institutional investors have recently made changes to their positions in UTHR. Torren Management LLC acquired a new stake in United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at $31,000. International Assets Investment Management LLC grew its holdings in shares of United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB grew its holdings in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.